Pyrotinib combined with fulvestrant in women with hormone receptor-positive (HR plus ) and human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer: A single-arm phase II clinical trial
D O I:
10.1158/1538-7445.SABCS21-P2-13-35